| Título: | Results of chemotherapy with BFM-87 protocol in children with acute myeloid leukemia at a referral center in the southwest of Iran: clinical characteristics and outcome |
| Autores: |
Pedram, Mohammad Hiradfar, AA |
| Fecha: | 2012-04-16 |
| Publicador: | Shahid Beheshti University of Medical Sciences |
| Fuente: |
Ver documento |
| Tipo: |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
| Tema: | No aplica |
| Descripción: | AbstractBackground: Leukemia is the most common malignancy in childhood, and acute myeloid leukemia (AML) is the second most common leukemia.AML still accounts for more than 30% of deaths from leukemia. AML is classified into several subgroups from M0 to M7 with different presentations, clinical features, and outcomes.Material and Methods: Between March 1996 and October 2003, 47 children with acute myeloid leukemia were treated with intensive chemotherapy using BFM-87 protocol after remission at Shafa hospital, Ahwaz, Iran. We compared the presenting features and outcomes of therapy in these children based on age, initial White Blood Cells (WBC) count, Central Nervous System involvement, FAB system types, and response to first induction treatment.Results: Younger children were more likely to have favorable risks and less likely to have induction deaths (p=0.03) and lower relapse risks (p=0.001). FAB types M2 and M4 showed a better first remission rate (p=0.01, p=0.02, respectively), regardless of age and gender. Two major risk factors for relapse after first remission were initial high WBC counts (p=0.01) and older age at the time of diagnosis (p=0.02). Overall survival (p=0.001), event-free survival (p=0.001), and disease-free survival were better (p<0.001) in younger children due to lower relapse rates (p=0.001).Discussion: Overall survival was 53% in the children with new AML who were on intensive chemotherapy with a median follow-up time of 5 years in our study. Relapse risk after first remission for the children who were on intensive chemotherapy alone was 34% in our study.Conclusion: Because of the potential morbidity and mortality usually related to allogeneic HSCT and also problems due to lack of sufficient HSCT possibility for some patients, several cooperative group trials now do not recommend HSCT for good- or standard- risk patients in their first remission. Results of our study were compatible with BFM , AML 10 and AML 12 groups trials in terms of overall survival, or relapse risk, or induction death risk factors. Keywords: acute myeloid leukemia, survival, chemotherapyReferences1. Lowenberg B, Downing JR, Burnett A. Acute Myeloid Leukemia: review article. NEJM 1999; 30: 1051-1062.2. Vardiman JW, Harris NL, Bruning RD. The World Health Organization(WHO) classification of myeloid neoplasms. Blood 2002; 100: 2292-2302.3. Clark JJ, Smith FO, Arceci RJ. Update in childhood acute myeloid leukemia: recent developments in the molecular basis of disease and nowel therapies. Curr Opin Hematol 2003; 10: 31-39.4. Benett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the acute leukemia. Br J Haematol 1976; 33: 451-458.5.Baumann I, Nenninger R, Harms H, et al. Image analysis detects lineage-specific morphologic markers in leukemic blast cells. Am J Clin Pathol 1996; 105: 23-30.6. Adachi K, Okumura M, Tanimoto M, et al. Analysis of immunophenotype, genotype, and lineage fidelity in blastic transformation of chronic myelogenous leukemia: a study of 20 cases. J lab Clin Med 1988; 111: 125-132.7. Harada N, Okamura S, Kubota A, et al. Analysis of acute myeloid leukemia cells by flowcytometry, introduction a new light-scattering classification. J Cancer Res Clin Oncol 1994; 120: 553-557.8. Tucker J, Dorey E, Gregory WM, et al. Immunophenotype of blast cells in acute myeloid leukemia may be a useful predictive factor for outcome. Hematol Oncol 1990; 8: 47-58.9. Akashi K, Traver D, Miyamoto T, et al. A clonogenic common myeloid progenitor that gives rise to all myeloid lineage. Nature 2000; 404: 193-197.10. Look AT. Oncogenic transcription factors in the human acute leukemias. Science 1997; 278: 1059-1064.11. Sutherland HJ, Blair A, Zapf RW. Characterization of a hierarchy in human acute myeloid leukemia progenitor cells. Blood 1996; 87: 4754-4761.12. Lapidot T, Sirard C, Vomoor J, et al. A cell initiating human acute myeloid leukemia after transplantation into SCID mice. Nature 1994; 367: 645-648.13. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997; 3: 730-737.14. Galigiuri MA, Strout MP, Gilliland DG.Molecular biology of acute myeloid leukemia. Semin Oncol 1997;24:3244.15. Arceci RJ. Progress and controversies in the treatment of pediatric acute myelogenous leukemia. Curr Opin Hematol 2002; 9: 353-360.16. Kersey JH. Fifty years of studies of the biology and therapy of childhood leukemia. Blood 1997; 90(11): 4243-4251.17. Arceci RJ, Golub T. Acure myelogenous leukemia In: Pizzo and D. Poplack, Editors. Principles and Practice of Pediatric Oncology. Lippincott Williams and Wilkins: Philadelphia, 2006: 591-644.18. Chen AR, Alonzo TA, Woods WG, Arceci RJ. Current controversies: which patients with acute myeloid leukemia should receive a bone marrow transplantation –an American view. Br J Haematol 2002; 118(2): 378-384.19. Burnett AK, Wheatley K, Goldstone AH, et al. The value of allogeneic bone marrow transplant in patients with acute myeloid leukemia at differing risk of relapse: results of the UK MRC AML 10 trial. Br J Haematol 2002; 118(2): 385-400.20. Creutzig U, Reinhardt D. Current controversies: which patients with acute myeloid leukemia should receive a bone marrow transplantation –a European view. Br J Haematol 2002; 118(2): 365-377.21. Bleakley M, Lau L, Shaw PJ, Kaufman A. Bone marrow transplantation for pediatric AML,in first remission: a systemic review and meta-analysis. Bone Marrow Transplant 2002; 29: 843-852.22. Creutzig U, Ritter J, Schellong G. Identification oftwo risk groups in childhood acute myelogenousleukaemia after therapy intensification in studyAML-BFM-83 as compared with study AML-BFM-78. Blood. 1990;75:1932-1940.23. Lie SO, Jonmundsson G, Mellander L, SiimesMA, Yssing M, Gustafsson G. A population basedstudy of 272 children with acute myeloid leukaemiatreated on two consecutive protocols withdifferent intensity: best outcome in girls, infantsand children with Down’s syndrome. Br J Haematol.1996;94:82-88.24. Woods WG, Kobrinsky N, Buckley JD, et al.Timed-sequential induction therapy improvespost remission outcome in acute myeloid leukaemia:a report from the Children’s Cancer Group.Blood. 1996;87:4979-4989.25. Stevens RF, Hann IM, Wheatley K, Gray RG.Marked improvements in outcome withchemotherapyalone in paediatric acute myeloid leukaemia:results of the United Kingdom Medical ResearchCouncil’s 10th AML trial. Br J Haematol.1998;101:130-140.26. Van Wering ER, Kamps WA. Acute leukaemia ininfants: a unique pattern of acute nonlymphocyticleukaemia. Am J Pediatr Hematol Oncol. 1986;8:220-224.27. Pui CH, Kalwinsky DK, Schell MJ, Mason CA,Mirro J, Dahl GV. Acute nonlymphoblastic leukaemiain infants: clinical presentation and outcome.J Clin Oncol. 1988;6:1008-1013.28. Pui C-H, Raimondi SC, Srivasta et al. Prognosticfactors in infants with acute myeloid leukaemia.Leukemia. 2000;14:684-687.29. Vormoor J, Ritter J, Creutzig U, et al. Acute myeloidleukaemia in children under 2 years—experiencesof the West German AML studies BFM-78, -83 and -87. Br J Cancer. 1992;66(suppl xviii):S63–S67.30. Grier HE, Gelber RD, Camitta BM, et al. Prognosticfactors in childhood acute myelogenous leukaemia.J Clin Oncol.1987;5:1026-1032.31. Gibson BE, Webb DKH, Wheatley K. Does transplantin first CR have a role in paediatric AML? Areview of the MRC AML 10 & 12 trials. Blood.2000;96:522a.32. Wheatley K, Burnett AK, Goldstone AH, et al. Asimple, robust and highly predictive prognosticindex for the determination of risk-directedtherapy in acute myeloid leukemia derived fromthe MRC AML 10 trial. Br J Haematol. 1999;107:69-79.33. Cassileth PA, Begg CB, Silber R, et al. Prolonged unmaintained remission after intensive consolidation therapy in adult acute myeloid leukemia. Cancer Treat rep 1987; 71: 137-140.34. Cassileth PA, Andersen JW, Bennett JM, et al. Escalating the intensity of post-remission therapy improves the outcome in acute myeloid leukemia: ECOG experience. The Eastern Cooperative Oncology Group. Leukemia 1992; 6: 116-119.35. Cassileth PA, Lynch E, Hines JD, et al. Varing intensity of postremission therapy in acute myeloid leukemia. Blood 1992; 79: 1924-1930.36. Baehner RL, Kennedy A, Sather H, et al. Characteristic of children with acute nonlymphocytic leukemia in long-term continuous remission: a report for childrens Cancer Study Group. Med Pediatr Oncol 1981; 9: 393-403.37. Tallman MS, Rowlings PA, Milone G, et al. Effect of postremission chemotherapy before human leukocyte anigen-identical sibling transplantation for acute myeloid leukemia in first complete remission. Blood 2000; 96: 1254-1258.38. Frassoni E, Labopin M, Gluckman E, et al. Results of allogeneic bone marrow transplantation for acute leukemia have improved in Europe with time- a report of the acute leukemia working patty of the European group for blood and marrow transplantation(EBMT). Bone Marrow Transplant 1996; 17: 13-18.39. Creutzig U, Ritter J, Zimmermann M, et al. Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of study Acute Myeloid Leukemia-Berlin-Frankfurt-Munser 93. J Clin Oncol 2001; 19: 2705-2713.40. Woods WG, Neudorf S, Gold S, et al. A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation and aggressive chemotherapy in children with acute myeloid leukemia in remission: a report from the Children's Cancer Group. Blood 2001; 97: 56-62.41. Amadori S, Testi AM, Arico M, et al. Prospectivecomparative study of bone marrow transplantationtransplantationand postremission chemotherapy for childhood acute myelogenous leukemia. J Clin Oncol.1993;11:1046-1054.42. Zittoun RA, Mandelli F, Willemze R, et al. Autologousor allogeneic bone marrow transplantation comparedwith intensive chemotherapy in acute myelogenousleukemia. NEngl J Med. 1995;332:217-223.43. Ravindranath Y, Yeager AM, Chang MN, et al.Autologous bone marrow transplantation versusintensive consolidation chemotherapy for acutemyeloid leukemia in childhood. NEngl J Med.1996;334:1428-1434.44. Stevens RF, Hann IM, Wheatley K, Gray RG.Marked improvements in outcome with chemotherapyalone in paediatric acute myeloid leukaemia:results of the United Kingdom Medical ResearchCouncil’s 10th AML trial. Br J Haematol.1998;101:130-140.45. Cassileth PA, Harrington DP, Appelbaum FR, etal. Chemotherapy compared with autologous orallogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med. 1998;339:1649-1656.46. Nesbit ME, Buckley JD, Feig SA, et al. Chemotherapy for induction of remission of childhood acute myeloid leukemia followed by marrow transplantation or multiagent chemotherapy: a report from the Childrens Cancer Group. J ClinOncol. 1994;12:127-135.47. Pinkel D, Woods WG, Lange B, Smith F, Alonzo T. Treatment of children with acute myeloid leukemia. Blood. 2001;97:3673-3675.48. Gertjan J.L. Kaspers, Christian M. Zwaan. Pediatric acute myeloid leukemia: toward high-quality cure of all patients. Hematologica. 2007; 92:1519-1532.49. Creutzig U, Zimmermann M, et al. Less Toxicity by Optimizing chemotherapy, but not by Addition of Granulocyte Colony-Stimulating Factor in Children and Adolescents with Acute Myeloid Leukemia: Results of AML-BFM 98. Journal of Clinical Oncology. 2006; 24:4499-4506. |
| Idioma: | Inglés |
1 Health and Education - 2 por Akbari, Mohammad Esmaeil | 6 Effectiveness of Mindfulness-Based Cognitive Therapy on Reduction of Depression and Anxiety Symptoms in Mothers of Children With Cancer por Mehranfar, Mojtaba; Dept. of Counselling, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran,Younesi, Jalal; Dept. of Counselling, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran,Banihashem, Abdollah; Dept. of Internal Medicine and Paediatrics, University of
Medical Sciences, Mashhad, Iran |
2 The Study of DNA Methylation of bax Gene Promoter in Breast and Colorectal Carcinoma Cell Lines por Alipour, Mohsen; Dept. of Cell and Molecular Biology, School of Biology, College of Science, University of Tehran, Tehran, Iran,Zargar, Seyed Jalal; Dept. of Cell and Molecular Biology, School of Biology, College of Science, University of Tehran, Tehran, Iran,Safarian, Shahrokh; Dept. of Cell and Molecular Biology, School of Biology, College of Science, University of Tehran, Tehran, Iran,Fouladdel, Shamile; Dept. of Pharmacology and Toxicology, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran,Azizi, Ebrahim; Dept. of Pharmacology and Toxicology, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
Biotechnology Research Center, Tehran University of Medical Sciences, Tehran, Iran,Jafargholizadeh, Naser; Dept. of Cell & Molecular Biology, School of Biology, College of Science, University of Tehran, Tehran, Iran | 7 Prevention and Management of Mucositis in Patients With Cancer: a Review Article por [wlia, ّatemeh; Dept. of Oral Medicine, Yazd Shahid Sadoughi University of Medical Sciences, Yazd, Iran,«azemeini, ُeidkazem; Burn hospital, Yazd Shahid Sadoughi University of Medical Sciences, Yazd, Iran,gholami, neda; Dept. of Oral Medicine, Yazd Shahid Sadoughi University of Medical Sciences, Yazd, Iran |
3 Cancer Prevention; Cancer Risk Management por Akbari, Mohammad Esmaeil | 8 Psychosocial Care for Breast Cancer: Physicians' Perspective por Kaviani, Ahmad; Department of surgery, Tehran University of Medical Sciences, Tehran, Iran,Mehrdad, N; Iranian Center for Breast Cancer (ICBC), Academic Center for Education, Culture and Research (ACECR), Tehran, Iran,Yunesian, M; school of Public Health , Environmental Research Center, Tehran University of Medical Sciences, Tehran, Iran,Shakiba, B; Students’ Scientific Research Center, Tehran University of Medical Sciences, Tehran, Iran,Ebrahimi, M; Iranian Center for Breast Cancer (ICBC), Academic Center for Education, Culture and Research (ACECR), Tehran, Iran,Majidzadeh, K; Iranian Center for Breast Cancer (ICBC), Academic Center for Education, Culture and Research (ACECR), Tehran, Iran,Akbari, ME; Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran |
4 Euthanasia in Cancer Patients, Islamic Point of View por Mousavi, SM; Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran,Akbari, A; Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran,Akbari, ME; Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran,Najd Sepas, H; Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran | 9 Cell Survival Entropy and Cellular Resistance Activation Dose: Effect of Calprotectin on Gastric Adenocarcinoma Cell Line por Rezaei-Tavirani, Mostafa,Rahmati-Roodsari, Mohammad,Mirzaie, Mehdi,Amini Geram, Pooneh,Sobhi, Sara |
5 Evaluation of Prognostic Factors In Patients with Metastatic Breast Cancer por Saeidi Saedi, H,Seilanian Toosi, M,Mirsadraei, M,Roodbari, S | 10 Antiphospholipid Antibodies in Neoplastic Patients por Mortazavizadeh, MR,Sadeghmanesh, R |